Increased intestinal permeability has been suggested as an important pathogenic factor in Crohn's disease."' Information on gastrointestinal permeability in Crohn's disease is scanty, however. In some studies different probe molecules were given by mouth, but the observations were conflicting maybe because the part of the gastrointestinal tract in which the probes were absorbed was not defined. To our knowledge, absorption from a defined intestinal segment has not previously been investigated in Crohn's disease.
We therefore measured the permeability of ileal segments during surgery for Crohn's disease or for colonic carcinoma. The showed decreasing excretion with rising molecular weight of PEG. In Crohn's disease, the mean urinary excretion of PEG was always greater than in the carcinoma patients, and showed little variation according to molecular weight. The intergroup differences in PEG absorption were significant in the 678-942 dalton range.
There were no differences in six hour urine volume between the two groups, Crohn patients excreted 391 Patients with Crohn's disease were reported to have increased intestinal permeability to orally administered lactulose, but impaired absorption of mannitol." 12 Uptake of radiolabelled Cr-EDTA was increased in Crohn's disease of the small intestine, but appeared to be unaffected in Crohn's colitis, whereas radiolabelled Tc-DPTA showed increased absorption in both types of involvement, with no difference between the two.'3'4 In earlier investigations with ingested PEG, we found that patients with ileocaecal Crohn's disease had impaired absorption of both PEG 400 and PEG 1000, and also diminished selectivity of the intestinal mucosa against larger molecules.'0151 6 A recent report described increased intestinal permeability to oral PEG 400 in Crohn's disease patients and in their clinical healthy relatives. 17 Investigations using peroral probe molecules thus do not reveal the site of absorption, inflamed or otherwise, in the intestine. Our method of measuring permeability intraoperatively, in an intestinal segment converted into a tied loop, circumvents this problem. To our knowledge, no previous investigator has clearly shown increased permeability in a well defined, inflamed segment of intestine in man.
Although the duration of exposure to probe molecules was relatively short, the absorption of almost all sizes was sufficient for identification in urine in the patients with Crohn's disease. In the patients with colon carcinoma, the PEG uptake in general was less and in regard to larger molecules it was frequently insufficient for detection in the urine. Despite the relatively small numbers of patients, we thus showed significantly increased permeability to PEG, in at any rate the 678-942 dalton range, in Crohn's disease as compared with colon carcinoma. We also confirmed our earlier findings'' 16 of diminished selectivity of the mucosal barrier in Crohn's disease, permitting larger molecules to be absorbed in amounts almost equalling the uptake of small ones. The intergroup differences in permeability indices were further indications of this mucosal alteration. Our findings accord with an investigation of exsorption of intravenous polyvinyl v pyrrolidone (mean molecular weight 33000 dalton) into the lumen of an intubated, inflamed segment of small intestine in Crohn's disease, which showed increased exsorption and loss of selectivity of the mucosal barrier. '8 Derangement of mucosal barrier function has been suggested as a prime factor in the development of chronic inflammatory bowel disease. ' 
